Induction of body weight loss through RNAi-knockdown of APOBEC1 gene expression in transgenic rabbits

PLoS One. 2014 Sep 12;9(9):e106655. doi: 10.1371/journal.pone.0106655. eCollection 2014.

Abstract

In the search of new strategies to fight against obesity, we targeted a gene pathway involved in energy uptake. We have thus investigated the APOB mRNA editing protein (APOBEC1) gene pathway that is involved in fat absorption in the intestine. The APOB gene encodes two proteins, APOB100 and APOB48, via the editing of a single nucleotide in the APOB mRNA by the APOBEC1 enzyme. The APOB48 protein is mandatory for the synthesis of chylomicrons by intestinal cells to transport dietary lipids and cholesterol. We produced transgenic rabbits expressing permanently and ubiquitously a small hairpin RNA targeting the rabbit APOBEC1 mRNA. These rabbits exhibited a moderately but significantly reduced level of APOBEC1 gene expression in the intestine, a reduced level of editing of the APOB mRNA, a reduced level of synthesis of chylomicrons after a food challenge, a reduced total mass of body lipids and finally presented a sustained lean phenotype without any obvious physiological disorder. Interestingly, no compensatory mechanism opposed to the phenotype. These lean transgenic rabbits were crossed with transgenic rabbits expressing in the intestine the human APOBEC1 gene. Double transgenic animals did not present any lean phenotype, thus proving that the intestinal expression of the human APOBEC1 transgene was able to counterbalance the reduction of the rabbit APOBEC1 gene expression. Thus, a moderate reduction of the APOBEC1 dependent editing induces a lean phenotype at least in the rabbit species. This suggests that the APOBEC1 gene might be a novel target for obesity treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • APOBEC-1 Deaminase
  • Animals
  • Animals, Genetically Modified
  • Apolipoprotein B-48 / blood
  • Base Sequence
  • Cholesterol / blood
  • Cytidine Deaminase / genetics*
  • Diet, High-Fat
  • Gene Expression*
  • Gene Knockdown Techniques*
  • Humans
  • Intestinal Mucosa / metabolism
  • Liver / metabolism
  • Molecular Sequence Data
  • Phenotype
  • RNA Editing / genetics
  • RNA Interference*
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • RNA, Small Interfering / metabolism
  • Rabbits
  • Transgenes
  • Triglycerides / blood
  • Weight Loss*

Substances

  • Apolipoprotein B-48
  • RNA, Messenger
  • RNA, Small Interfering
  • Triglycerides
  • Cholesterol
  • APOBEC-1 Deaminase
  • APOBEC1 protein, human
  • Cytidine Deaminase

Grants and funding

This study was funded by Agence Nationale de la Recherche (ANR-06-RIB-FATSTOP) to ObeTherapy as leader of the program and to INRA. Sandrine Braud and Itzik Harosh are employees of and shareholders in ObeTherapy Biotechnology. ObeTherapy Biotechnology provided support in the form of salaries for authors SB and IH, had a direct role in the study design, and analysis, decision to publish, and preparation of the manuscript.